Belatacept for heart transplant patients
Treatments studied
Part of Heart & circulation clinical trials.
This study tests whether a drug called belatacept can safely help your body accept a new heart without rejecting it, and may reduce the need for other strong immune-suppressing medicines. If you are getting a heart transplant for the first time and have certain immune markers, this trial may be an option for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are receiving your first heart transplant (no other organs at the same time).
- You have had the Epstein-Barr virus (EBV) in the past (a common virus that most people have had).
- You are not pregnant and agree to use effective birth control.
- You do not have active infections like HIV, hepatitis B or C, or untreated tuberculosis.
- You have not had treatment that lowers antibodies before transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial checks whether using heart-monitoring blood tests and biopsy results can help customize (optimize) immune-suppression medication soon after your transplant. It aims to keep the transplanted heart safe while avoiding over- or under-treatment.
This study tests whether combining everolimus with a lower dose of a standard anti-rejection drug (calcineurin inhibitor) can help heart transplant patients in Korea have fewer side effects while keeping their new heart healthy.
This trial tests whether Thymoglobulin® is safe and how well it works in people getting their first heart transplant. It may help doctors fine-tune medicines used to prevent the body from rejecting the new heart.
This trial studies whether belatacept, an anti-rejection medicine given by IV, can work for people receiving their first heart transplant. It aims to see if it prevents rejection safely for patients and whether it fits better than standard approaches for certain candidates.
This trial studies whether belatacept can be used after a heart transplant to help protect kidney function over time. It focuses on people who already have (or are at risk for) worsening kidney function after transplant, while avoiding those with certain infections or rejection concerns.
This trial looks at replacing standard anti-rejection medicines (tacrolimus, a type of CNI, plus mycophenolate and possibly prednisone) with belatacept in adults who have early kidney graft dysfunction 3–12 months after a kidney transplant. It aims to see if belatacept can control rejection and protect kidney function in the right patients.
Hear when a new Heart Transplant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.